Clinical Nuclear Medicine最新文献

{"title":"18 F-FDG PET/CT Identified Rectal Malignancy Earlier Than 68 Ga-FAPI PET/CT.","authors":"Hui Wang, Minggang Su","doi":"10.1097/RLU.0000000000005800","DOIUrl":"10.1097/RLU.0000000000005800","url":null,"abstract":"<p><p>A 69-year-old man with esophageal cancer underwent dual-tracer PET/CT using 18 F-FDG and 68 Ga-FAPI during his treatment. At baseline, neither scan showed abnormal uptake in the rectum. Three months later, an interim 18 F-FDG PET/CT revealed focal uptake in the rectum, while the 68 Ga-FAPI PET/CT showed no abnormal findings. Seventeen months later, he received a third dual-tracer PET/CT for surveillance. Both 18 F-FDG and 68 Ga-FAPI PET/CT detected abnormal activity in the same area of the rectum​​​​​​ . The lesion was later confirmed as adenocarcinoma by histopathology after surgery. Our case demonstrated the 18 F-FDG PET/CT could identify the rectal malignancy before 68 Ga-FAPI PET/CT.</p>","PeriodicalId":10692,"journal":{"name":"Clinical Nuclear Medicine","volume":" ","pages":"534-536"},"PeriodicalIF":9.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coronary Arteries Involvement in Giant Cell Arteritis Diagnosis Using 2-[ 18 F]FDG-PET/CT.","authors":"Julien Kunsch, Olivier Espitia, Françoise Kraeber-Bodéré, Marine Eustache, Bastien Jamet","doi":"10.1097/RLU.0000000000005807","DOIUrl":"10.1097/RLU.0000000000005807","url":null,"abstract":"<p><p>Coronary artery involvement in giant cell arteritis (GCA) is rare but can lead to severe complications, including myocardial infarction and death. We present unique 2-[ 18 F]fluorodeoxyglucose positron emission tomography/computed tomography (2-[ 18 F]FDG-PET/CT) findings in a 91-year-old woman with GCA. In addition to typical aortic and supra-aortic involvement, this scan revealed intense FDG uptake in the coronary arteries, including the left main trunk, left anterior descending, circumflex, and right coronary arteries. This inflammatory pattern was consistent with GCA, with no signs of atherosclerosis on coronary CT angiography. Early identification of coronary inflammation enabled timely immunosuppressive therapy, potentially preventing fatal outcomes.</p>","PeriodicalId":10692,"journal":{"name":"Clinical Nuclear Medicine","volume":" ","pages":"e370-e371"},"PeriodicalIF":9.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143596499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic Accuracy of PSMA-targeted 18F-Florastamin PET/CT in Intermediate-risk Patients With Suspected Prostate Cancer.","authors":"Jimin Yuei, Wonho Jung, Kyoung Sook Won, Teak-Jun Shin, Byoung Je Kim, Mi Sun Choe, Hye Ra Jung, Byung-Hoon Kim, Hae Won Kim","doi":"10.1097/RLU.0000000000005798","DOIUrl":"https://doi.org/10.1097/RLU.0000000000005798","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to evaluate the diagnostic accuracy of 18F-Florastamin prostate-specific membrane antigen (PSMA) positron emission tomography-computed tomography (PET/CT) in detecting intermediate-risk prostate cancer and compare its performance with multiparametric magnetic resonance imaging (mpMRI).</p><p><strong>Patients and methods: </strong>Fifty-nine patients with suspected intermediate-risk prostate cancer (prostate-specific antigen: 3-20 ng/mL) were prospectively enrolled. All participants underwent examination with 18F-Florastamin PET/CT and mpMRI, with imaging results assessed using the PSMA-Reporting and Data System and Prostate Imaging-Reporting and Data System Version 2.1 scoring systems, respectively. Prostate biopsy served as the reference standard. Diagnostic metrics, including sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), accuracy, and area under the receiver operating characteristic curve (AUC), were calculated to compare the 2 modalities.</p><p><strong>Results: </strong>PSMA PET/CT demonstrated a sensitivity of 72.4%, specificity of 83.3%, and overall accuracy of 78%, with an AUC of 0.78 (95% CI: 0.67-0.89). Contrastingly, mpMRI showed a higher sensitivity (89.7%) but lower specificity (66.7%), achieving the same overall accuracy of 78% and an AUC of 0.78 (95% CI: 0.68-0.88). No statistically significant difference in AUC was observed between the 2 modalities (P=0.967). While PSMA PET/CT offered higher specificity and PPV, reducing false-positive results, mpMRI excelled in sensitivity and NPV, minimizing false negatives.</p><p><strong>Conclusions: </strong>18F-Florastamin PSMA PET/CT demonstrated comparable diagnostic accuracy to mpMRI, with the added benefit of higher specificity. These findings suggest that PSMA PET/CT could complement mpMRI in the diagnostic evaluation of intermediate-risk prostate cancer, enhancing patient stratification and aiding clinical decision-making.</p>","PeriodicalId":10692,"journal":{"name":"Clinical Nuclear Medicine","volume":"50 6","pages":"e352-e359"},"PeriodicalIF":9.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143958268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Scintigraphic Improvement of Primary Intestinal Lymphangiectasia in a Patient Treated With Alpelisib for a PIK3CA-Related Overgrowth Spectrum.","authors":"Julien Dubois, Fabien Vauchot","doi":"10.1097/RLU.0000000000005680","DOIUrl":"10.1097/RLU.0000000000005680","url":null,"abstract":"<p><strong>Abstract: </strong>A 33-year-old man with primary intestinal lymphangiectasia (Waldmann disease) associated with PIK3CA-related overgrowth spectrum was explored using 99m Tc serum albumin scintigraphy before and during treatment by alpelisib, a specific PIK3CA inhibitor. Before treatment, scintigraphic images evidenced a focal uptake on the right colonic angle 4 hours postinjection (p.i.), diffusing to the transverse and left colon 24 hours p.i., compatible with a diffuse colonic exudation. Significant scintigraphic improvement was observed with a disappearing of the right colonic angle uptake 4 hours p.i. and later images 14 months after alpelisib introduction.</p>","PeriodicalId":10692,"journal":{"name":"Clinical Nuclear Medicine","volume":" ","pages":"527-530"},"PeriodicalIF":9.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143432486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intratumoral Heterogeneity of Primary Breast Cancer on 18 F-FES PET/CT and dbPET Anticipated a Heterogeneous Response to Chemotherapy.","authors":"Yurika Kitano, Kanae K Miyake, Yoichi Shimizu, Masahiro Kawashima, Yuji Nakamoto","doi":"10.1097/RLU.0000000000005660","DOIUrl":"10.1097/RLU.0000000000005660","url":null,"abstract":"<p><strong>Abstract: </strong>A 59-year-old woman with cT3N3M1 invasive breast cancer (ER low positive, PgR positive, HER2 negative) underwent PET/CT and dedicated breast PET scans using 18 F-FDG and 18 F-fluoroestradiol ( 18 F-FES). While most primary tumor regions displayed low FES uptake, regions of high FES uptake were also identified. Following chemotherapy with the paclitaxel and bevacizumab, 18 F-FDG PET/CT demonstrated a favorable response, but residual disease was noted in areas with high FES uptake on the pretreatment images. This case illustrated that 18 F-FES PET can depict intratumoral heterogeneity within the primary tumor, which was strongly associated with a heterogeneous response to subsequent chemotherapy.</p>","PeriodicalId":10692,"journal":{"name":"Clinical Nuclear Medicine","volume":" ","pages":"541-543"},"PeriodicalIF":9.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143028029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intense Prostate-specific Membrane Antigen Avid Hepatic Metastatic Lesions Shortly After Finishing 6 Cycle Pluvicto Treatment: Challenging and Reflects.","authors":"Xiaofei Wang, Thomas Hogan, Kody Heubach","doi":"10.1097/RLU.0000000000005789","DOIUrl":"10.1097/RLU.0000000000005789","url":null,"abstract":"<p><p>A 71-year-old man was diagnosed with prostate cancer in 2012. After treatment with hormone, chemo, and combinations subsequently, the baseline prostate-specific membrane antigen PET scan revealed 130+ nodal and osseous metastatic lesions. After 4 doses of pluvicto, a partial response was appreciated. However, new intense prostate-specific membrane antigen avid hepatic lesions occupied around 30% of the liver with poorly differentiated metastatic prostate cancer 55 days after the last dose of pluvicto and markedly elevated prostate-specific antigen. This case highlights the need for vigilant monitoring and alternative treatment strategies.</p>","PeriodicalId":10692,"journal":{"name":"Clinical Nuclear Medicine","volume":" ","pages":"523-524"},"PeriodicalIF":9.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143499585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FDG PET/CT in a Case of Marjolin Ulcer of the Scalp Over a Long-standing Burn Scar.","authors":"Mehul Dulet, Sameer Taywade, Vikrant Verma, Rajesh Kumar","doi":"10.1097/RLU.0000000000005688","DOIUrl":"10.1097/RLU.0000000000005688","url":null,"abstract":"<p><strong>Abstract: </strong>Marjolin ulcer is a malignant degeneration of previously injured skin, long-established scars, and wounds. This malignant transformation is most implicated in full-thickness burns; however, it may be associated with vaccination sites, pressure sores, venous stasis, and many other conditions causing chronic scar or wound formation. These lesions are aggressive and carry a poor prognosis. FDG PET/CT is an excellent diagnostic aid to differentiate these lesions from benign inflammation, to evaluate the primary malignant site and its extent and depth, and to evaluate metastasis. SUV max has been noted to be significantly higher in Marjolin ulcer than in benign conditions.</p>","PeriodicalId":10692,"journal":{"name":"Clinical Nuclear Medicine","volume":" ","pages":"e374-e375"},"PeriodicalIF":9.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143370620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FDG PET/CT of Atypical Myeloid Sarcoma After CAR T-Cell Therapy.","authors":"Daniel L Gray, Joanna Fair","doi":"10.1097/RLU.0000000000005759","DOIUrl":"10.1097/RLU.0000000000005759","url":null,"abstract":"<p><p>A 23-year-old man with a history of Ph-Like B-cell acute lymphoblastic leukemia (B-ALL) with JAK2 rearrangement presented with innumerable skin lesions developing over 1 week. Before presentation, he had multiple relapses of his B-ALL and underwent autologous UCD-19 chimeric antigen receptor (CAR) T-cell therapy. Lesions appeared 1.5 months after completion of therapy. Biopsies showed new onset myeloid sarcoma (MS), with continued remission of B-ALL. 18 F-FDG PET/CT showed numerous markedly hypermetabolic soft tissue lesions located in the skin and subcutaneous tissues, muscles, osseous structures, mucosa, pleura, mediastinum, peritoneum, retroperitoneum, and testes.</p>","PeriodicalId":10692,"journal":{"name":"Clinical Nuclear Medicine","volume":" ","pages":"e362-e364"},"PeriodicalIF":9.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143482405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"68 Ga-Pentixafor PET/CT-Based Response Evaluation and its Prognostic Value in Multiple Myeloma: Comparison With IMWG and 18 F-FDG-Based Response.","authors":"Harneet Kaur, Suraj Kumar, Ankit Watts, Charanpreet Singh, Man Updesh Singh Sachdeva, Sreejesh Sreedharanunni, Rajender Kumar, Pankaj Malhotra, Baljinder Singh","doi":"10.1097/RLU.0000000000005731","DOIUrl":"10.1097/RLU.0000000000005731","url":null,"abstract":"<p><strong>Purpose: </strong>68 Ga-Pentixafor PET/CT targets CXCR4 receptors and provides superior diagnostic accuracy in multiple myeloma (MM) compared with 18 F-FDG PET/CT. However, its role in response evaluation remains unexplored. We propose a 68 Ga-Pentixafor PET/CT-based response evaluation criterion and evaluate its utility compared with International Myeloma Working Group (IMWG) criteria and 18 F-FDG PET/CT-based response.</p><p><strong>Patients and methods: </strong>In this prospective single-center study, 40 treatment-naive myeloma patients were recruited between February 2021 and April 2023. Both 68 Ga-Pentixafor and 18 F-FDG PET/CT were performed at baseline and at follow-up (7.2 mo-median). Response to treatment was evaluated using the proposed 68 Ga-Pentixafor PET/CT criteria and compared with responses assessed by IMWG and 18 F-FDG PET/CT. Progression-free survival (PFS) and overall survival (OS) were analyzed and compared using Kaplan-Meier survival curves.</p><p><strong>Results: </strong>Among the 40 newly diagnosed MM patients [median age: 56.5 years (IQR 45.25 to 63.75); 24 men], 68 Ga-Pentixafor PET/CT was positive in a greater proportion of patients than 18 F-FDG PET/CT [90% (36/40) vs. 67.5% (27/40); P =0.02] thus, adequately evaluated response in additional 27.5% (11/40) of cases. Using the proposed criteria for 68 Ga-Pentixafor PET/CT, significant differences in PFS were observed across response categories [complete response (CR)-not reached, partial response (PR)-26.2 mo, progressive disease (PD)-15.3 mo; P =0.001]. Among patients achieving ≥very good partial response (VGPR) as per IMWG, those with positive 68 Ga-Pentixafor PET/CT had shorter PFS compared with those with negative findings (median PFS: 34.2 mo vs. not reached; P =0.056), whereas no significant difference was noted with 18 F-FDG PET/CT ( P =0.68). In addition, on follow-up of patients with negative 18 F-FDG at the response, those with discordant 68 Ga-Pentixafor findings had significantly shorter PFS (17.73 mo vs. not reached; P =0.010) compared with those with concordant negative findings.</p><p><strong>Conclusions: </strong>68 Ga-Pentixafor PET/CT offers a more accurate assessment of treatment response and prognosis in MM patients, adding valuable information beyond the IMWG and 18 F-FDG PET/CT-based criteria.</p>","PeriodicalId":10692,"journal":{"name":"Clinical Nuclear Medicine","volume":" ","pages":"e331-e339"},"PeriodicalIF":9.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143572284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Syphilitic Lymphadenitis and Clavicle Pathological Fracture Mimicking Malignant Tumor on 18 F-FDG PET/CT.","authors":"Hongzheng Zhang, Youwen Dong, Sheng Dai","doi":"10.1097/RLU.0000000000005638","DOIUrl":"10.1097/RLU.0000000000005638","url":null,"abstract":"<p><strong>Abstract: </strong>A 66-year-old woman presented with 9 days of left clavicle pain, with no history of recent trauma. CT images showed a left clavicle fracture with a surrounding soft tissue mass. An 18 F-FDG PET/CT scan revealed increased FDG uptake in the tonsils, multiple lymph nodes, and the pathologically fractured clavicle, initially suggesting malignancy. However, serologic tests and pathology confirmed syphilitic lymphadenitis and osteomyelitis. Given the inguinal and cervical lymphadenopathy with FDG uptake, potential bone destruction, or pathological fractures mimicking malignancy, syphilis should be considered in the differential diagnosis. Serologic testing and Treponema pallidum screening are essential.</p>","PeriodicalId":10692,"journal":{"name":"Clinical Nuclear Medicine","volume":" ","pages":"525-526"},"PeriodicalIF":9.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142946110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}